vs
Side-by-side financial comparison of Axil Brands, Inc. (AXIL) and NovaBay Pharmaceuticals, Inc. (NBY). Click either name above to swap in a different company.
Axil Brands, Inc. is the larger business by last-quarter revenue ($8.1M vs $4.8M, roughly 1.7× NovaBay Pharmaceuticals, Inc.). Axil Brands, Inc. runs the higher net margin — 8.7% vs -25.5%, a 34.2% gap on every dollar of revenue. On growth, NovaBay Pharmaceuticals, Inc. posted the faster year-over-year revenue change (126.1% vs 5.2%). Axil Brands, Inc. produced more free cash flow last quarter ($906.4K vs $-1.7M). Over the past eight quarters, NovaBay Pharmaceuticals, Inc.'s revenue compounded faster (42.5% CAGR vs 12.1%).
Axil Brands, Inc. is a U.S.-headquartered company that designs, manufactures and markets premium hearing protection products, audio enhancement devices and personal audio accessories. Its offerings include custom-fit earplugs, Bluetooth-enabled hearing buds for work, sports and leisure use, serving both consumer and professional segments across global markets.
NovaBay Pharmaceuticals, Inc. is an Emeryville, California based clinical-stage biopharmaceutical company, focused on products for eye care. Major products include Avenova, cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis. and NeutroPhase, used in treatment of Necrotizing Fasciitis
AXIL vs NBY — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2024
| Metric | | |
|---|---|---|
| Revenue | $8.1M | $4.8M |
| Net Profit | $704.9K | $-1.2M |
| Gross Margin | 68.1% | 65.2% |
| Operating Margin | 11.1% | -37.2% |
| Net Margin | 8.7% | -25.5% |
| Revenue YoY | 5.2% | 126.1% |
| Net Profit YoY | 11.2% | 70.5% |
| EPS (diluted) | $0.09 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $8.1M | — | ||
| Q3 25 | $6.9M | — | ||
| Q2 25 | $5.8M | — | ||
| Q1 25 | $6.9M | — | ||
| Q4 24 | $7.7M | $4.8M | ||
| Q3 24 | $5.9M | $0 | ||
| Q2 24 | $6.5M | $2.4M | ||
| Q1 24 | $6.5M | $2.6M |
| Q4 25 | $704.9K | — | ||
| Q3 25 | $334.3K | — | ||
| Q2 25 | $-245.6K | — | ||
| Q1 25 | $576.7K | — | ||
| Q4 24 | $633.7K | $-1.2M | ||
| Q3 24 | $-109.8K | $-1.2M | ||
| Q2 24 | $49.5K | $-1.6M | ||
| Q1 24 | $781.1K | $-3.2M |
| Q4 25 | 68.1% | — | ||
| Q3 25 | 67.6% | — | ||
| Q2 25 | 70.0% | — | ||
| Q1 25 | 71.7% | — | ||
| Q4 24 | 71.1% | 65.2% | ||
| Q3 24 | 71.0% | — | ||
| Q2 24 | 71.5% | 66.3% | ||
| Q1 24 | 71.5% | 68.2% |
| Q4 25 | 11.1% | — | ||
| Q3 25 | 6.0% | — | ||
| Q2 25 | 0.8% | — | ||
| Q1 25 | 8.4% | — | ||
| Q4 24 | 8.7% | -37.2% | ||
| Q3 24 | -2.4% | — | ||
| Q2 24 | 2.6% | -67.4% | ||
| Q1 24 | -1.6% | -87.1% |
| Q4 25 | 8.7% | — | ||
| Q3 25 | 4.9% | — | ||
| Q2 25 | -4.3% | — | ||
| Q1 25 | 8.3% | — | ||
| Q4 24 | 8.2% | -25.5% | ||
| Q3 24 | -1.9% | — | ||
| Q2 24 | 0.8% | -66.0% | ||
| Q1 24 | 12.1% | -122.2% |
| Q4 25 | $0.09 | — | ||
| Q3 25 | $0.04 | — | ||
| Q2 25 | $-0.03 | — | ||
| Q1 25 | $0.07 | — | ||
| Q4 24 | $0.08 | — | ||
| Q3 24 | $-0.02 | $-1.92 | ||
| Q2 24 | $0.11 | $-1.37 | ||
| Q1 24 | $0.04 | $-29.95 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.0M | $430.0K |
| Total DebtLower is stronger | $138.3K | — |
| Stockholders' EquityBook value | $11.1M | $-129.0K |
| Total Assets | $16.2M | $3.4M |
| Debt / EquityLower = less leverage | 0.01× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.0M | — | ||
| Q3 25 | $4.1M | — | ||
| Q2 25 | $4.8M | — | ||
| Q1 25 | $4.7M | — | ||
| Q4 24 | $5.2M | $430.0K | ||
| Q3 24 | $4.1M | $776.0K | ||
| Q2 24 | $3.3M | $751.0K | ||
| Q1 24 | $4.9M | $1.8M |
| Q4 25 | $138.3K | — | ||
| Q3 25 | $139.2K | — | ||
| Q2 25 | $140.2K | — | ||
| Q1 25 | $141.0K | — | ||
| Q4 24 | $143.3K | — | ||
| Q3 24 | $144.3K | — | ||
| Q2 24 | $146.6K | — | ||
| Q1 24 | — | — |
| Q4 25 | $11.1M | — | ||
| Q3 25 | $10.2M | — | ||
| Q2 25 | $9.7M | — | ||
| Q1 25 | $9.7M | — | ||
| Q4 24 | $8.8M | $-129.0K | ||
| Q3 24 | $7.9M | $1.1M | ||
| Q2 24 | $7.7M | $-617.0K | ||
| Q1 24 | $8.8M | $160.0K |
| Q4 25 | $16.2M | — | ||
| Q3 25 | $15.4M | — | ||
| Q2 25 | $12.9M | — | ||
| Q1 25 | $13.0M | — | ||
| Q4 24 | $13.7M | $3.4M | ||
| Q3 24 | $11.4M | $3.9M | ||
| Q2 24 | $11.0M | $3.9M | ||
| Q1 24 | $12.7M | $5.4M |
| Q4 25 | 0.01× | — | ||
| Q3 25 | 0.01× | — | ||
| Q2 25 | 0.01× | — | ||
| Q1 25 | 0.01× | — | ||
| Q4 24 | 0.02× | — | ||
| Q3 24 | 0.02× | — | ||
| Q2 24 | 0.02× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $934.8K | $-1.7M |
| Free Cash FlowOCF − Capex | $906.4K | $-1.7M |
| FCF MarginFCF / Revenue | 11.1% | -35.4% |
| Capex IntensityCapex / Revenue | 0.3% | 0.1% |
| Cash ConversionOCF / Net Profit | 1.33× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $934.8K | — | ||
| Q3 25 | $-739.2K | — | ||
| Q2 25 | $194.4K | — | ||
| Q1 25 | $-169.9K | — | ||
| Q4 24 | $1.0M | $-1.7M | ||
| Q3 24 | $897.3K | $-2.4M | ||
| Q2 24 | $-336.6K | $-1.4M | ||
| Q1 24 | $-912.8K | $-2.0M |
| Q4 25 | $906.4K | — | ||
| Q3 25 | $-747.6K | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $-258.2K | — | ||
| Q4 24 | $941.1K | $-1.7M | ||
| Q3 24 | — | — | ||
| Q2 24 | $-394.9K | — | ||
| Q1 24 | $-922.1K | $-2.0M |
| Q4 25 | 11.1% | — | ||
| Q3 25 | -10.9% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -3.7% | — | ||
| Q4 24 | 12.2% | -35.4% | ||
| Q3 24 | — | — | ||
| Q2 24 | -6.1% | — | ||
| Q1 24 | -14.3% | -75.3% |
| Q4 25 | 0.3% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 0.9% | 0.1% | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.9% | 0.0% | ||
| Q1 24 | 0.1% | 0.1% |
| Q4 25 | 1.33× | — | ||
| Q3 25 | -2.21× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.29× | — | ||
| Q4 24 | 1.59× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -6.80× | — | ||
| Q1 24 | -1.17× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXIL
| Hearing Enhancement And Protection | $7.8M | 95% |
| Other | $378.9K | 5% |
NBY
| Other | $2.4M | 51% |
| Total Product Revenue | $2.3M | 49% |
